|
Published by: Urch Publishing
Published: Feb. 1, 2008 - 102 Pages
Table of Contents
- Chapter 1: The Nature of the European Pharmaceutical Supply Chain
- The pharmaceutical supply chain
- Pharmaceutical manufacturers in the EU
- Pharmacies in the EU
- Wholesalers in the EU
- The hospital sector
- Prewholesaling
- History of the pharmaceutical supply chain
- Dynamics in the supply change
- Relationships within the supply chain
- Vertical integration
- New changes in the supply change
- Outlook for the supply chain
- Global lessons for the supply chain
- Case study: Consolidation among Japanese pharmaceutical wholesalers
- European status of the supply chain
- Stability of the European supply chain
- Product shortages in the supply chain
- Case study: Vaccine shortages and the effect on the supply chain
- Case study: Supply chain disruption in Latin America
- Traceability throughout the supply chain
- Counterfeit products
- Internet trading and pharmaceuticals
- Parallel trade
- The view of pharmaceutical manufacturers
- The view of parallel importers
- Legalities of parallel trade
- Exhaustion of intellectual property rights
- Repackaging and relabelling of products
- Consumer views of intellectual property rights
- The European Union
- History of the EU
- The set-up of the EU
- EU law
- Primary legislation
- Secondary legislation
- Case-law
- Decision-making in the EU
- The institutions of the EU
- The European Economic Area (EEA)
- The creation of the EEA
- EU Enlargement and the EEA
- The Euro
- The Euro and pharmaceuticals
- Chapter 2: Challenges for medicine wholesalers in Europe
- The role of the pharmaceutical wholesaler
- Channels of distribution
- Wholsalers and the Single European market
- Wholesaler opposition to supply quotas
- Case study: Bayer's Export Policy for Adalat
- Case study: Syfait versus GlaxoSmithKline
- Wholesaler views of Direct-to-Phamacy distribution
- Crossborder mergers and acquisitions
- Case study: Double acquisition by Phoenix ensures successful market entry into Croatia
- EU harmonisation and the outlook for pan-European wholesaleing
- The major players in pan-European wholesaleing
- Celesio AG
- The PHOENIX Group
- OPG Group
- Alliance Boots
- European regulations for wholesalers
- Guidelines on Good Distribution Practice of Medicinal Products for Human Use (94/C 63/03)
- Lack of harmonisation and the supply chain
- Wholesaler technology solutions
- Electronic data interchange
- Collaborative planning forecasting and replenishment
- Enterprise resource planning
- Wholesalers develop value added services
- Case study: GEHE Pharma Handel chosen as "Best-Practice-Enterprise" for value added services
- Case study: PHOENIX wins pharmacy partner award
- Order fulfilment packages
- Database technology
- Electronic point-of-sale technology
- Bar coding
- Case study: US highlights benefits of bar code and RFID technologies
- Case study: Pfizer France reviews the RFID system for Viagra
- Case study: AstraZeneca opts for mass serialisation to prevent counterfeiting
- European wholesaler opinions on technological solutions
- Warehouse technology
- Dispensing technology
- Techology in the future of pharma distribution
- Consumers and e-commerce
- Case study: DocMorris
- Pharmaceutical distribution in UK
- Pharmaceutical distribution in France
- Case study: Industry support of the Masters Degree in Pharmaceutical Distribution at University of Limoges
- Pharmaceutical distribution in Germany
- Pharmaceutical distribution in Italy
- Case study: IBS introduces supply chain management solutions into the Italian pharmaceutical market
- Pharmaceutical distribution in Spain
- Pharmaceutical distribution in Switzerland
- Case study: Galenica expands its service offerings
- Chapter 3: Manufacturers start to control the ditribution of pharmaceuticals
- Pharmaceutical manufacturers in Europe
- The pharmaceutical industry and the supply chain
- The role of pharmaceuticals
- Drug development and innovation
- Cost containment
- The pharmaceutical market
- Lack of harmonisation in the EU pharmaceutical market
- Counterfeiting
- Pharmaceutical industry efforts to combat counterfeiting
- Manufacturers exert control over the supply chain
- The Office of Fair Trading investigation
- Implications of changes in the supply chain
- Service standards to patients
- Rationale behind changes in the supply chain
- Pfizer's feedback on Direct-to-Pharmacy distribution
- Case study: Pfizer UK's Direct-to-Pharmacy website
- Reaction to the Office of Fair Trading enquiry
- AstraZeneca changes its supply chain arrangements
- Sanofi-Aventis changes its supply chain arrangements
- Napp Pharmaceuticals changes its supply chain arrangements
- Novartis considers changes to supply chain arrangements
- Eli Lilly considers changes to supply chain arrangements
- Astellas adopts direct distribution for Transplant Medicines
- Patients and healthcare
- Case study: The International Alliance of Patients' Organizations
- Pharmaceutical manufacturers and the developing countries
- Collaborations with healthcare providers
- Case study: Novartis makes agreement with the World Health Organization for distribution of malaria treatment
- Case study: Diversion of anti-retroviral drugs destined for Africa
- Anti-diversion tactics
- Chapter 4: Pharmacy and the Future of Medicines Distribution
- Pharmacies in Europe
- Additional pharmacy services
- Differences in pharmacy regulations
- Hospital pharmacy in Europe
- Wholesaler Margins and VAT
- Rebates and discounts
- Distribution of OTCs
- Generics
- Independent pharmacies
- Pharmacy chains
- Wholesaler involvement in pharmacy chains
- Pharmacy purchasing groups
- Supermarkets
- Drugstore chains
- Mail-order pharmacy
- Removing restrictions in the European pharmacy sector
- Case study: European Commission challenges Italian legislation concerning pharmacies
- Case study: European Commission challenges Spanish legislation concerning pharmacies
- Case study: European Commission challenges Austrian legislation concerning pharmacies
- Sale of non-prescription products outside pharmacies
- Implications of liberalisation in the European pharmacy sector
- Liberalisation of the pharmacy sector and accessibility
- Liberalisation of the pharmacy sector and market dominance
- Liberalisation of the pharmacy sector and quality of service
- Pharmacies and changes in the supply chain
- REFERENCES
- List of Figures
- Figure 1.1 Outline of the Supply Chain
- Figure 1.2 Number of pharmacists (per 1000 population)
- Figure 1.3 Total revenue of European pharmaceutical wholesalers (without VAT)
- Figure 1.4 Worldwide Vaccine Market
- Figure 1.5 Share of parallel imports in European pharmacy markets
- Figure 2.1 Number of Full-line Wholesalers
- Figure 2.2 Average gross margin of wholesalers in 9 West Europe Countries
- Figure 2.3 Celesio AG Wholesale Revenue by Market (2006)
- Figure 2.4 Celesio AG Pharmacy Revenue by Market (2006)
- Figure 2.5 Phoenix Group Turnover (2002 - 2007)
- Figure 2.6 Breakdown of OPG Sales (2006)
- Figure 2.7 Alliance Boots Wholesale Division Revenue (Q1,2,3 2006)
- Figure 2.8 Percentage of electronic orders from pharmacies to wholesalers
- Figure 3.1 Pharmaceutical R&D Expenditure in Europe 1195 - 2006
- Figure 3.2 Pharmaceutical R&D Expenditure across Europe
- Figure 3.3 NHS expenditure per person in the UK
- Figure 3.4 Community prescribing in the UK: Prescriptions Per head
- Figure 3.5 Patient satisfaction with quality and effectiveness of healthcare received
- Figure 3.6 Patient satisfaction with ability to access information on new medicines or treatments
- Figure 4.1 Number of Public Pharmacies (12 European Countries)
- Figure 4.2 Pharmacy sales per inhabitant Europe (€)
- Figure 4.3 Number of Hospital Pharmacies in 8 Countries
- Figure 4.4 VAT rates applied to prescription medicines across Europe
- Figure 4.5 Share of generics in European pharmaceutical markets
- Figure 4.6 Percent change in number of pharmacies N, E, N, A, F, S(1995 - 2005)
- Figure 4.7 UK Pharmacy respondent views on potential costs of setting up a separate Pfizer account for DTP
- List of Tables
- Table 1.1: Types of manufacturer medicines
- Table 1.2: The institutions of the EU
- Table 1.3: Adoption of the euro
- Table 2.1: OPG's activities in Europe
- Table 2.2: Summary of GDP Guidelines
- Table 2.3: The BAPW's Gold Standard of Good Distribution Practice by Pharmaceutical Wholesalers as endorsed by the MHRA
- Table 2.4: Process of adoption of IBS supply chain management solution by Itriafarma
- Table 3.1 Key areas of focus for the International Medicinal Products Anti-Counterfeiting Taskforce (IMPACT)
- Table 3.2: Overall risks due to DTP identified by OFT
- Table 3.3: Implications of reduced service standards due to DTP (adapted from OFT, 2007)
- Table 3.4: Anti-diversion tactics employed by pharmaceutical manufacturers and cited by WHO
- Table 4.1: Goals of the EAHP
- Table 4.2: Summary of liberalised pharmacy sector in "case study" countries chosen by ÖBIG
- Table 4.3: Summary of regulated pharmacy sector in "reference study" countries chosen by ÖBIG
Abstract"Each day millions of patients across Europe rely on the supply chain to deliver the medicines they need"
Pharmaceutical Distribution in Europe - The Emergence of Direct-to-Pharmacy Supply from URCH Publishing, is a market report that comprehensively reviews the business of medicines distribution in Europe.
The traditional model of pharmaceutical supply chain in Europe is under threat as major pharmaceutical manufacturers in the UK attempt to change the way they distribute their products. The adoption of a Direct-to-pharmacy (DTP) model by some of the industry's most powerful players in the UK signifies a new trend that could spread across Europe.
REPORT STRUCTURE
The report is logically divided into four chapters.
Chapter 1 provides a comprehensive history and overview of the key issues related to the pharmaceutical supply chain in Europe, including European law, parallel trade and the recent EU enlargement.
Chapter 2 fully reviews the role of pharmaceutical wholesale companies. Issues tackled include regulations, technologies used, plus reviews of the major players such as Celesio, Phoenix Group and OPG and the market in France, Germany, Italy and the UK.
Chapter 3 discusses how pharmaceutical manufacturers organise the distribution of their products. The current vogue for direct-to-pharmacy is analysed, as is reaction to the UK's OFT report. Recent changes by major manufacturers to their supply chain are summarised.
Chapter 4 looks at the pressures that the pharmacy sector is under. Liberalisation still in its infancy in some countries and pharmacists are being encouraged to expand their role beyond just dispensing. Changes to the supply chain could have a profound effect on established business models.
The report provides an objective perspective on important industry questions, such as:
- Will direct-to-pharmacy become the dominant method of drug distribution
- Do pharmacists have a future beyond the administration of dispensing?
- Are counterfeit medicines now a major issues that the industry has to deal with?
- What is the current thinking on the role of parallel trade in the European market?
Key features of the report include:
- Contains 20 Case studies including these companies, Bayer, DocMorris, Galencia, IBS, Novartis, Phoenix and Pfizer,
- Unbiased synopsis of the UK's Office of Fair Trading's (OFT) report into the medicines' supply chain
- Overview of the European pharmaceutical supply chain and the stakeholders involved in medicines distribution
- Insight into the aggressive Pan-European expansion strategies of some wholesalers
- Summary of regulations governing pharmaceutical wholesaling and pharmacy
With 14 Tables and 26 Figures this report is essential reading for anyone working in the pharmaceuticals supply chain including manufacturers, wholesalers, distributors and pharmacists.
Companies and organisations mentioned in the report include:
3i, Alliance Unichem, Amedis UE AG, Apteka, Associazione Distributori Farmaceutici, Astellas Pharma, AstraZeneca, Authentix, Azienda Speciale Farmacie Comunali Riunite, Bayer, British Association of Pharmaceutical Wholesalers, Celesio AG, Chambre Syndicale de la Répartition Pharmaceutique, Chiron, Dainippon Sumitomo Pharma, Der Bundesverband des pharmazeutischen Großhandels, DocMorris, EAEPC, Eli Lilly, Europharm, Farmaceutica Bolognese, Farmacija d.d, FDA, Galenica Group, Galexis, GEHE Pharma Handel, Groupement International de la Répartition Pharmaceutique, HgCapita, Independent Pharmacy Federation, International Pharmaceutical Excipients Council, Itriafarma, Mediceo Paltac Holdings, Medifarm Velebit, MediService, Merck, Neuhaus Partners, Norsk Medisinaldepot, Novartis, OPG Group, Pfizer, Pharmexx, PhRMA, PHOENIX group, Plus Pharmacie, Retail Working Group, Sanofi-Aventis, Surgency, Syncra Systems, Takeda, Tamro, Unione Farmaceutica, Viafarma, Voigt AG
USE THIS REPORT TO:
- Identify key areas that will change in the pharmaceutical market structure over the next five years.
- Support internal planning and decision-making with an external perspective founded on detailed analysis and transparent market forecasts.
- Understand how the regulatory environment could change to reflect new business models.
Remember URCH Publishing's healthcare management reports are designed to help business executives make properly informed and timely business decisions.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
